Friday, December 28, 2018

CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib

SEATTLE, Dec. 28, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) announced today the completion of full enrollment of 150 patients in the PAC203 Phase 2 study of pacritinib. The Company expects to report the determination of the optimal dose of pacritinib in mid-2019 following a...



from PR Newswire: https://prn.to/2SpGQUa
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)